Tomas Kalincik

Comparative effectiveness in multiple sclerosis: A methodological comparison

Izanne Roos, Ibrahima Diouf, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Raed Alroughani, Alexandre Prat, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison, Patrizia Sola, et al.

Journal article  |  2023  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND: In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trial..

Optimal sensor location and direction to accurately classify people with early-stage multiple sclerosis using gait stability.

L Eduardo Cofré Lizama, Maya G Panisset, Liuhua Peng, Ying Tan, Tomas Kalincik, Mary P Galea

Journal article  |  2023  |  Gait Posture

BACKGROUND: The local divergence exponent (LDE) has been used to assess gait stability in people with multiple sclerosis (pwMS). A..

Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis

Yew Li Dang, Vivien TY Yong, Sifat Sharmin, Piero Perucca, Tomas Kalincik

Journal article  |  2023  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND: Multiple sclerosis patients experience 3-6 times more seizures than the general population, but observations vary amon..

Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity.

Tim Spelman, Dana Horakova, Serkan Ozakbas, Raed Alroughani, Marco Onofrj, Tomas Kalincik, Alexandre Prat, Murat Terzi, Pierre Grammond, Francesco Patti, Tunde Csepany, Cavit Boz, Jeannette Lechner-Scott, Franco Granella, Francois Grand'Maison, Anneke van der Walt, Chao Zhu, Helmut Butzkueven, undefined MSBase Study Group

Journal article  |  2023  |  Mult Scler Relat Disord

BACKGROUND: Patients with relapsing-remitting multiple sclerosis (RRMS) who experience relapses on a first-line therapy (interfero..

Neuroimaging characteristics may aid in diagnosis, subtyping, and prognosis in autoimmune encephalitis

James Broadley, Robb Wesselingh, Paul Beech, Udaya Seneviratne, Chris Kyndt, Katherine Buzzard, Cassie Nesbitt, Wendyl D'Souza, Amy Brodtmann, Richard Macdonell, Tomas Kalincik, Terence J O'Brien, Helmut Butzkueven, Mastura Monif

Journal article  |  2022  |  NEUROLOGICAL SCIENCES

OBJECTIVE: To examine the utility of neuroimaging characteristics as biomarkers of prognosis in seropositive autoimmune encephalit..

Confirmed disability progression as a marker of permanent disability in multiple sclerosis

S Sharmin, C Malpas, J Lechner-Scott, M Slee, P McCombe, S Vucic, E Butler, S Hodgkinson, M Barnett, O Skibina, A van der Walt, K Buzzard, C Shaw, A Kermode, B Taylor, N Shuey, R Macdonell, H Butzkueven, T Kalincik

Journal article  |  2022  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND AND PURPOSE: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); how..

Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity

Vilija G Jokubaitis, Maria Pia Campagna, Omar Ibrahim, Jim Stankovich, Pavlina Kleinova, Fuencisla Matesanz, Daniel Hui, Sara Eichau, Mark Slee, Jeannette Lechner-Scott, Rodney Lea, Trevor J Kilpatrick, Tomas Kalincik, Philip L De Jager, Ashley Beecham, Jacob L McCauley, Bruce Taylor, Steve Vucic, Louise Laverick, Karolina Vodehnalova, et al.

Journal article  |  2022  |  BRAIN

Multiple sclerosis is a leading cause of neurological disability in adults. Heterogeneity in multiple sclerosis clinical presentat..

External validation of a clinical prediction model in multiple sclerosis

Nahid Moradi, Sifat Sharmin, Charles B Malpas, Vahid Shaygannejad, Murat Terzi, Cavit Boz, Bassem Yamout, Samia J Khoury, Recai Turkoglu, Rana Karabudak, Nevin Shalaby, Aysun Soysal, Ayse Altintas, Jihad Inshasi, Talal Al-Harbi, Raed Alroughani, Tomas Kalincik, Study Grp MSBase

Journal article  |  2022  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND: Timely initiation of disease modifying therapy is crucial for managing multiple sclerosis (MS). OBJECTIVE: We aimed to..

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

Tim Spelman, Serkan Ozakbas, Raed Alroughani, Murat Terzi, Suzanne Hodgkinson, Guy Laureys, Tomas Kalincik, Anneke Van der Walt, Bassem Yamout, Jeannette Lechner-Scott, Aysun Soysal, Jens Kuhle, Jose Luis Sanchez-Menoyo, Yolanda Blanco Morgado, Daniele La Spitaleri, Vincent van Pesch, Dana Horakova, Radek Ampapa, Francesco Patti, Richard Macdonell, et al.

Journal article  |  2022  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multiple sclerosis (MS), was establ..

Updated Results of the COVID-19 in MS Global Data Sharing Initiative Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Steve Simpson-Yap, Ashkan Pirmani, Tomas Kalincik, Edward De Brouwer, Lotte Geys, Tina Parciak, Anne Helme, Nick Rijke, Jan A Hillert, Yves Moreau, Gilles Edan, Sifat Sharmin, Tim Spelman, Robert McBurney, Hollie Schmidt, Arnfin B Bergmann, Stefan Braune, Alexander Stahmann, Rod M Middleton, Amber Salter, et al.

Journal article  |  2022  |  NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION

BACKGROUND AND OBJECTIVES: Certain demographic and clinical characteristics, including the use of some disease-modifying therapies..